Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.
Skip to main content
Fig. 1 | Alzheimer's Research & Therapy

Fig. 1

From: Cerebrospinal fluid β2-microglobulin promotes the tau pathology through microglia–astrocyte communication in Alzheimer's disease

Fig. 1

Transformed baseline CSF β2M in participants classified according to the NIA-AA criteria (A, B, C, D) and age (E). Levels of transformed CSF β2M were significantly lower in S1, T-, N- and mid-life group. Notes: CSF β2M fitted the normal distribution after log10 transformation and then standardized by z-scale. Transformed plasma β2M was computed with the One-way ANCOVA for comparison of means while Fisher's LSD was employed for post hoc test. Models included age, gender, education, APOE ε4 status as covariates. Significant effects (P < 0.05) are shown in bold. Abbreviations: CSF, cerebrospinal fluid; β2M, β2-microglobulin; NIA-AA, National Institute on Aging- Alzheimer’s Association; S, stage; A, amyloidosis; T, tau pathology; N, neurodegeneration; SNAP, suspected non-Alzheimer’s pathophysiology; APOE, Apolipoprotein E

Back to article page

Alzheimer's Research & Therapy

ISSN: 1758-9193